Malaria in pregnancy Infections and Infestations Malaria
Conditions
Interventions
Study Arm A: Artemether-lumefantrine given as four tablets twice daily for three days for each IPTp dose three times during the pregnancy
Study Arm B: Sulphadoxine-pyrimethamine given as three tablets
Sponsors
UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR)
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. Pregnant with a gestational age between 20 to 28 weeks 2. Residing within a radius of 20 miles from the hospital 3. Attending AnteNatal Clinic (ANC) and has not yet received regular programme IPTp with SP 4. Attending ANC and last received anti-malarial treatment greater than one month ago 5. Gives informed consent for study participation 6. Able to come for follow-up
Exclusion criteria
Exclusion criteria: 1. Known allergy to SP or artemether-lumefantrine 2. Previously diagnosed with Glucose-6-phosphate dehydrogenase deficiency 3. Presently ill with a medical condition requiring admission to hospital 4. Known patient with cardiac disease or arrhythmia 5. Intrauterine foetal death in the current pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Prevalence and severity of placental parasitaemia at delivery | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Prevalence of low birth weight (less than 2500 g) at delivery 2. Prevalence and severity of peripheral parasitaemia during pregnancy until delivery 3. Prevalence of anaemia (haemoglobin less than 10 g/dl) at 34 weeks and at delivery | — |
Countries
Uganda
Outcome results
None listed